Zydus Lifesciences Q4FY26: Profit up 9%, buyback

Results land during market hours

Zydus Lifesciences reported its Q4FY26 earnings during market hours on May 19, 2026, with headline numbers showing a clear year-on-year improvement. Consolidated net profit for the quarter was reported at ₹1,272.5 crore, up 8.7% from the year-ago period. Revenue from operations rose 16% to ₹7,587 crore, reflecting broad-based momentum across key businesses. The company attributed the profit rise to robust performance across markets. Another financial snapshot cited Q4 net profit at ₹1,592.9 crore, up 14.6% year-on-year, after adjusting for exceptional items. That same snapshot also disclosed a one-time spend of ₹397.5 crore related to the Mirabegron litigation settlement during the quarter. The mixed profit figures across reports underscore the role of exceptional items and reporting adjustments in interpreting quarterly profitability.

Market reaction: stock closes higher on results

The stock ended the session at ₹1,018.90 on the BSE, up ₹27.80 or 2.80% from the previous close of ₹991.10. It opened at ₹995.00 and spent much of the day in a tight range, before seeing a sharper move after 14:00 hours. Zydus Lifesciences hit an intraday high of ₹1,048.00 and an intraday low of ₹995.00. The day’s VWAP was reported at ₹1,028.11, suggesting the late spike saw some profit-taking into the close. Market depth at close was described as fully on the buy side in the visible order book. The session’s move also marked a fresh weekly high, as the stock had closed around ₹991 the day earlier.

Q4FY26: topline growth led by multiple engines

Q4 revenue growth was supported by India formulations, international formulations, consumer wellness, and MedTech. India formulations revenue rose 14% year-on-year to ₹1,752.8 crore in Q4FY26, contributing 24% to consolidated revenue as cited. International markets formulations revenue grew 45% year-on-year to ₹804 crore, supported by demand across emerging markets and Europe. Consumer wellness revenue climbed 61% year-on-year to ₹1,463.3 crore, helped by skin and hair care brands and international operations. MedTech reported quarterly revenue of ₹327.5 crore. The segment detail indicates that growth was not concentrated in one geography or line of business.

Profitability metrics and exceptional items

One set of consolidated highlights put Q4FY26 EBITDA at ₹2,554.4 crore, up 20.2% year-on-year, with margin expansion of 110 basis points to 33.7%. Net profit in those highlights was stated at ₹1,592.9 crore, up 14.6% year-on-year, adjusted for exceptional items. The quarter included a one-time spend of ₹397.5 crore towards the Mirabegron litigation settlement. Separately, another report pegged consolidated net profit at ₹1,272.5 crore, up 8.7% year-on-year. Taken together, the disclosures show that operational improvement was accompanied by exceptional charges that can change the headline profit number depending on treatment.

FY26: full-year growth and differing reported PAT figures

For the full year ended March 31, 2026, revenue from operations was reported at ₹27,148.4 crore, up 16.8% year-on-year, with EBITDA of ₹8,475.1 crore, up 20.1% year-on-year. Full-year EBITDA margin was cited at 31.2%, up 80 basis points from 30.4% in FY25. Full-year net profit in the consolidated highlights was stated at ₹5,456.4 crore, up 15.0% year-on-year. Separately, another market report cited FY26 consolidated net profit at ₹5,040 crore, up 11.37% year-on-year, and described full-year revenue growth at 16.81% to ₹27,148.4 crore. An earlier summary also stated that full-year net profit increased 11% while revenue rose 17%. Readers tracking year-on-year profit should note which profit definition a given report is using.

Dividend and buyback: what the board approved

The board recommended a dividend described as “100%” for FY2025-26. Another disclosure specified a final dividend of Re 1 per equity share of face value Re 1, subject to shareholder approval at the AGM scheduled for August 11, 2026. Alongside the dividend, the board approved a share buyback of up to ₹1,100 crore at a price of ₹1,150 per share. The buyback size was also specified as up to 95.65 lakh equity shares via tender offer. May 29, 2026 was set as the record date for determining eligible shareholders for the buyback. The buyback price was described as about a 16% premium to the May 18, 2026 close (variously cited around ₹991.10 to ₹991.20).

Key numbers at a glance

Price action context: range, returns, and levels

On May 19, the stock traded between ₹995.00 and ₹1,048.00 and closed at ₹1,018.90. The 52-week high was cited at ₹1,059.05 and the 52-week low at ₹835.50. A separate stock-performance snapshot reported volume at 58.77 lakh shares for the day and an exchange circuit range of ₹892.00 to ₹1,090.20. The weekly move was also described as a recovery from about ₹928 at the start of the week of May 12 to a close above ₹1,018 on May 19. Market capitalisation was cited around ₹1,02,525 crore in one source, while another cited around ₹99,727.85 crore. The variation reflects differences in timing and data providers, but both place the company near the ₹1 lakh crore mark.

Why the quarter matters for investors

The quarter combined strong revenue growth with visible shareholder-return actions. Business performance in India, international formulations, and consumer wellness suggests multiple drivers rather than dependence on a single market. At the same time, the Mirabegron litigation settlement expense shows how legal and one-time items can influence headline profitability. The buyback size and price, and the record date disclosure, provide clear near-term event markers for shareholders considering the tender route. Investors will also watch how the company sustains growth in international formulations after a strong 45% year-on-year quarter. For FY26, the reported improvement in margins adds a profitability angle alongside topline growth, based on the EBITDA numbers disclosed.

Conclusion

Zydus Lifesciences closed higher after reporting Q4FY26 revenue growth of 16% and profit growth in the high single digits, with additional disclosures highlighting stronger adjusted profitability alongside a one-time litigation settlement expense. The board’s dividend recommendation and ₹1,100 crore buyback at ₹1,150 per share added to the day’s focus. The next key dates flagged include the buyback record date of May 29, 2026 and the AGM scheduled for August 11, 2026 for dividend approval.